DEVELOPMENT OF MODERN BIOLOGICS AND CELL THERAPY PRODUCTS THROUGH GLOBAL CDMOs
Анотація
The majority of innovative ideas and disruptive technologies are nucleated at academic and educational institutions. However, these organizations have limited budgets and lack the process development and manufacturing infrastructure, particularly if their advanced products belong to different technological platforms. This gap can be closed by contract development and manufacturing organizations (CDMOs), which remain crucial to new drug process development, manufacturing and commercialization.
Посилання
Methods for inducing chondrogenesis Patent CA3060518A1, Peter G. Schultz, Arnab K. Chatterjee, Timothy M. Wright, John Wisler, Vadim Klyushnichenko, 2018
A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Sung Chang Lee, Jennifer S. Y. Ma, Min Soo Kim, Eduardo Laborda, Sei-Hyun Choi, Eric N. Hampton, Hwayoung Yun, Michelle T. Muldong, Christina N. Wu, Wenxue Ma, Anna A. Kulidjian, Christopher J. Kane, Vadim Klyushnichenko, Ashley K. Woods, Sean Joseph, John Wisler, Jing Li, Christina A. M. Jamieson, Peter G. Schultz, Chan Hyuk Kim, Travis S. Young, Sci Adv. 2021 Aug 11;7(33)
First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019). Liana Nikolaenko, Carolyn Mulroney, Peter A. Riedell, Ian W. Flinn, Jose Carlos Cruz, Rakhee Vaidya, Koen van Besien, Michael Emde, Vadim Klyushnichenko, Jonathan Strauss, Eduardo Laborda, Jing Li, Mohit Trikha, Peter G. Schultz, Travis S Young. Blood (2021), V.138 (Supplement 1): 2822.
